Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

July 27, 2021

Primary Completion Date

October 19, 2027

Study Completion Date

October 19, 2027

Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
DRUG

Iptacopan

Taken orally b.i.d. Dosage supplied: 200 mg Dosage form: hard gelatin capsule Route of administration: oral

Trial Locations (57)

970

Novartis Investigative Site, Hualien City

10002

Novartis Investigative Site, Taipei

10126

Novartis Investigative Site, Torino

10461

Montefiore Medical Center, The Bronx

15706

Novartis Investigative Site, Santiago de Compostela

20080

Novartis Investigative Site, Donostia / San Sebastian

20122

Novartis Investigative Site, Milan

20246

Novartis Investigative Site, Hamburg

29615

Prisma Health Upstate, Greenville

30912

Augusta University, Augusta

31059

Novartis Investigative Site, Toulouse

33014

Lakes Research, Miami Lakes

34093

Novartis Investigative Site, Istanbul

36061

Novartis Investigative Site, Bassano del Grappa

44093

Novartis Investigative Site, Nantes

44195

Cleveland Clinic Foundation, Cleveland

45147

Novartis Investigative Site, Essen

50134

Novartis Investigative Site, Florence

52074

Novartis Investigative Site, Aachen

59037

Novartis Investigative Site, Lille

63100

Novartis Investigative Site, Ascoli Piceno

75475

Novartis Investigative Site, Paris

83100

Novartis Investigative Site, Avellino

88586

Novartis Investigative Site, Kota Kinabalu

89081

Novartis Investigative Site, Ulm

90033

USC Norris Cancer Center, Los Angeles

91010

City Of Hope, Duarte

92868

Univ of California Irvine (Chao Family Comprehensive Cancer Center), Orange

93586

Novartis Investigative Site, Kuching

100730

Novartis Investigative Site, Beijing

119074

Novartis Investigative Site, Singapore

300020

Novartis Investigative Site, Tianjin

300052

Novartis Investigative Site, Tianjin

09090-790

Novartis Investigative Site, Santo André

01323-900

Novartis Investigative Site, São Paulo

708 52

Novartis Investigative Site, Ostrava

625 00

Novartis Investigative Site, Brno Bohunice

06202

Novartis Investigative Site, Nice

01307

Novartis Investigative Site, Dresden

01589

Novartis Investigative Site, Riesa

00161

Novartis Investigative Site, Roma

453-8511

Novartis Investigative Site, Nagoya

960 1295

Novartis Investigative Site, Fukushima

920 8641

Novartis Investigative Site, Kanazawa

259-1193

Novartis Investigative Site, Isehara

392-8510

Novartis Investigative Site, Suwa

565 0871

Novartis Investigative Site, Suita

160-0023

Novartis Investigative Site, Shinjuku Ku

606 8507

Novartis Investigative Site, Kyoto

951 8520

Novartis Investigative Site, Niigata

LT-08661

Novartis Investigative Site, Vilnius

6500HB

Novartis Investigative Site, Nijmegen

03080

Novartis Investigative Site, Seoul

06351

Novartis Investigative Site, Seoul

08036

Novartis Investigative Site, Barcelona

LS9 7TF

Novartis Investigative Site, Leeds

SE5 9RS

Novartis Investigative Site, London

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY